Results of a phase II trial with cystemustine at 90 mg/m2 as a first- or second-line treatment in advanced malignant melanoma : a trial of the EORTC Clinical Screening Group
Nom du journal : Melanoma Res
Année : 1999
Volume : 9
Page de départ : 1
Page de fin : 4